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Abstract
Background: Depressive disorders are frequent in epilepsy and associated with reduced seizure control. Almost
50% of interictal depressive disorders have to be classified as atypical depressions according to DSM-4 criteria.
Research has mainly focused on depressive symptoms in defined populations with epilepsy (e.g., patients admitted
to tertiary epilepsy centers). We have chosen the opposite approach. We hypothesized that it is possible to define
by clinical means a subgroup of psychiatric patients with higher than expected prevalence of epilepsy and seizures.
We hypothesized further that these patients present with an Acute Unstable Depressive Syndrome (AUDS) that
does not meet DSM-IV criteria of a Major Depressive Episode (MDE). In a previous publication we have
documented that AUDS patients indeed have more often a history of epileptic seizures and abnormal EEG
recordings than MDE patients (Vaaler et al. 2009). This study aimed to further classify the differences of depressive
symptoms at admittance and follow-up of patients with AUDS and MDE.
Methods: 16 AUDS patients and 16 age- and sex-matched MDE patients were assessed using the Symptomatic
Organic Mental Disorder Assessment Scale (SOMAS), the Montgomery and Åsberg Depression Rating Scale
(MADRS), and the Mini-Mental State Test (MMST), at day 2, day 4-6, day 14-16 and 3 months after admittance to a
psychiatric emergency unit. Life events were assessed with The Social Readjustment Rating Scale (SRRS) and The
Life Experience Survey (LES). We also screened for medication serum levels and illicit drug metabolites in urine.
Results: AUDS patients had significantly higher SOMAS scores (average score at admission 6.6 ± 0.8), reflecting
increased symptom fluctuation and motor agitation, and decreased insight and concern compared to MDE
patients (2.9 ± 0.7; p < 0.001). Degree of mood depression, cognition, life events, drug abuse and medication did
not differ between the two groups.
Conclusions: AUDS patients present with rapidly fluctuating mood symptoms, motor agitation and relative lack of
insight and concern. Seizures, epilepsy and EEG abnormalities are overrepresented in AUDS patients compared to
MDE patients. We suggest that the study of AUDS patients may offer a new approach to better understanding
epilepsy and its association with depressive disorders.
Trial registration: NCT00201474
Background
Depression is more frequent in patients with epilepsy
compared to the general population [1,2]. Every second
patient admitted to a tertiary epilepsy center may suffer
from concurrent depressive disorders [3,4]. Depression has
greater negative impact on quality of life than seizure
frequency or the number of prescribed antiepileptic drugs
[4-6]. In addition, depression in epilepsy is associated with
reduced seizure control [7-10] and dramatically increased
suicide risk [11-14] and health care costs [15]. Recent evi-
dence suggests that the relationship between epilepsy and
depression is bidirectional [2,16-18]. Thus, patients with
epilepsy are more likely to develop depressive disorders,
and patients with a history of depression or suicide
attempt have a higher risk of developing epilepsy.
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Interictal depressive disorders in patients with epilepsy
have unique manifestations that are poorly reflected in
the established classification systems ICD-10 and DSM-
IV [19-24]. Symptoms such as suicidal ideation, frustra-
tion intolerance, irritability and motor agitation can
rapidly alternate with symptom-free periods lasting one
to several days. Blumer and co-workers have called this
type of depression “an interictal dysphoric disorder with
a characteristic intermittent and pleomorphic sympto-
matology” [23]. Kanner has termed it the “dysthymic-
like disorder of epilepsy” [3]. Indeed, almost 50% of
interictal depressive disorders may have to be classified
as atypical depressions according to DSM-IV criteria
[23]. It can be concluded that the physician must be
cautious not to overlook atypical interictal mood distur-
bances. However, this sometimes leads to a well-known
clinical dilemma in which the patient tends to attribute
all mood disturbances to sub-clinical epileptic activity
(and consequently demands revision of antiepileptic
therapy), whereas the neurologist may not at all be con-
fident with the patient’s interpretation. Depression and
many types of epilepsy share indeed several pathogenic
mechanisms [7,8]. To determine when interictal mood
disturbance in a given patient is due to sub-clinical epi-
leptic activity and when not, is often impossible.
Clinical research on the association of depression and
epilepsy has for the sake of simplicity focused on
depressive symptoms in defined populations with epi-
lepsy (e.g., patients admitted to a tertiary epilepsy cen-
ter). This approach has the obvious disadvantage that
the study population is highly pre-selected. In order to
examine epilepsy and depression from a different angle,
we have therefore chosen the opposite approach in the
present study. We hypothesized that it is possible to
define by clinical means a subgroup of psychiatric
patients with a higher than expected prevalence of epi-
lepsy and seizures. We hypothesized further that this
patient group presents to the psychiatric emergency unit
with rapidly fluctuating mood symptoms that do not
meet DSM-IV criteria of a Major Depressive Episode
(MDE). For the purpose of the present study we have
called this presentation the Acute Unstable Depressive
Syndrome (AUDS). In a prospective study we have been
able to show that AUDS patients indeed more often
have a history of epileptic seizures [25] and abnormal
quantitative EEG recordings [26] than age- and sex-
matched MDE patients. The main aim of the present
paper was to further classify the differences of depres-
sive symptoms at admittance and follow-up of patients
with AUDS and MDE. For this purpose we have devel-
oped a 5-item diagnostic scale to measure the preva-
lence and degree of atypical depressive mood symptoms.
We have called this scale the Symptomatic Organic
Mental disorder Assessment Scale (SOMAS).
Methods
Study groups
During three years all patients (n = 1038) admitted to
the psychiatric emergency unit (n = 1984) at the psy-
chiatric division of St. Olav’s University Hospital in
Trondheim, Norway, were evaluated for inclusion in the
present study. The following criteria had to be fulfilled:
A. AUDS group: Patients had to present with a rapidly
developing psychiatric disorder starting within the pre-
vious 14 days. During this period the patient had to
exhibit at some time symptoms that - with the impor-
tant exception of the time criterion - met criteria for at
least two diagnoses in the Diagnostic and Statistical
Manual of Mental Disorders, fourth edition (DSM-IV)
Axis 1 categories [20]. One of these DSM-IV Axis 1
categories had to be a depressive episode as defined by
the Montgomery and Åsberg Depression Rating Scale
(MADRS) ≥ 20 [27]. All patients were assessed in co-
operation between experienced senior psychiatrists
(AEV, GM, OML). One of the following criteria lead to
exclusion: a psychiatric disorder due to intoxication;
dementia or cognitive impairment to such a degree that
informed consent could not be obtained; a diagnosis of
unstable personality disorder with identical symptoms at
former admissions; and lack of sufficient knowledge of
the English or Norwegian language. 28 (2.7%) of the
patients fulfilled the criteria for inclusion in the AUDS
group. Twelve of these were excluded due to the rea-
sons stated above. Sixteen AUDS patients entered the
study. The co-diagnoses (with exception of the time cri-
terion) in this group were DSM-IV 298.8 “brief psycho-
tic disorder” (9 patients), DSM-IV 300.1 “panic
disorder” (4 patients) and DSM-IV 296.0 “single manic
episode” (3 patients).
B. MDE group: This group consisted of acutely
admitted sex- and age-matched (+/- 5 years) patients
meeting criteria for current Axis 1 major depressive epi-
sode (MADRS ≥20). After inclusion of a patient in the
AUDS group, the first patient meeting MDE criteria and
giving informed consent to participate in the study was
recruited to the MDE group (n = 16).
Group assessments
Our pre-study clinical observations had indicated that
characteristic features of AUDS included fluctuating
psychiatric symptoms, suicidal ideation, motor agita-
tion (or relative lack of psychomotor retardation) when
depressed, and lack of ability to understand or explain
present symptoms. To test the validity of our observa-
tions we developed a 5-item scale with operational
scoring criteria for estimating prevalence and degree of
the symptoms we had noted. This is the Symptomatic
Organic Mental disorder Assessment Scale (SOMAS).
In a pre-study of patients consecutively admitted to
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the psychiatric emergency unit (n = 22), SOMAS
showed good inter-rater reliability and internal consis-
tency. It contains two main factors, one related to
motor symptoms (motor retardation versus agitation),
and one related to the insight and interest in one’s
own disorder (considerable effort, or lack thereof, in
finding an explanation). Compared to MADRS,
SOMAS measures a different concept than depression.
Item A is measuring the degree of observable fluctua-
tion in symptoms during the previous 24 hours. Item
B is measuring the degree of motor retardation and
item C the degree of increased motor activity during
the last 24 hours. Items B and C, assessed at the time
the patient is considered most depressed, are modified
from The Positive and Negative Syndrome Scale
(PANSS) for schizophrenia [28]. Item D is measuring
the degree of insight the patient has about his/her
affective symptoms. Item E is measuring the effort the
patient makes in finding an explanation for these
symptoms. Further information about Items A-E and
the scoring procedure can be found in Appendix.
Patients were assessed using SOMAS, MADRS [27]
and the Mini-Mental State Test (MMST) [29] at four
different time points: day 2, day 4-6, day 14-16 and 3
months after admittance. A MMST score < 25 was
regarded as a clinically relevant cognitive reduction [30].
Life events during the 6 months prior to admission were
rated with The Social Readjustment Rating Scale (SRRS)
[31], and life changes during the 12 months prior to
admittance with a 24-item version of The Life Experi-
ence Survey (LES) [32]. These scales allow for detection
of positive and negative life experiences as well as their
impact on the patient. Alcohol consumption was
assessed with The Alcohol Use Identification Test
(AUDIT) [33]. Current medication concentrations were
analyzed in blood samples, and drug use was screened
for by urine samples at admittance. During admissions
the patients were examined using MRI and serial EEG-
videometry as described previously [25,26]. Diagnoses
were set according to The Structural Clinical Interview
for DSM-IV (SCID-1) [34].
Statistical methods
Statistical differences between groups were analyzed
using the Student’s t-test and the Fisher exact test with
two-tailed p < 0.05 considered significant.
Ethics
All patients gave written informed consent. The study
was conducted in accordance with the Declaration of
Helsinki and approved by The Regional Medical
Research Ethics Committee, Central Norway.
Results
The clinical background data have been published pre-
viously [25]. The data are summarized in Table 1.
AUDS patients had significantly more often a history of
seizures and a diagnosis of epilepsy. They also had sig-
nificantly more often epileptiform activity and focal or
generalized slow activity on standard EEG.
In the five AUDS patients fulfilling clinical criteria for
epilepsy, two had juvenile generalised epilepsy syn-
dromes, both with generalized tonic-clonic (GTC) sei-
zures and absences. One had a syndrome of
posttraumatic localisation-related epilepsy with noctur-
nal seizures presumed to be secondarily generalized, and
two had scattered GTCs with a syndromic classification
that remained undetermined [25].
Table 1 Clinical background data of AUDS and MDE patients
AUDS patients
(n = 16; age 32y ± 11; 6 males)
MDE patients
(n = 16; age 33y ± 13; 6 males)
P value*
Problematic alcohol consumption 4 (n = 15) 4 (n = 13) ns
Alcohol withdrawal symptoms 0 3 ns
Drug abuse 1& 0 ns
Benzodiazepine medication 6 3 ns
Anti-epileptic medication for epilepsy # 4 0 ns
Anti-epileptic medication for other indications # 3 0 ns
Seizures in clinical history 6 0 0.018
Fulfilling clinical criteria for epilepsy 5 0 0.043
Focal or generalized slow, or epileptiform EEG activity
(≥ 2 pathological features)
8 1 0.015
Cerebral MRI pathology 2 (n = 13) 2 (n = 13) ns
Pathological findings at neurological bedside examination
indicative of CNS pathology
3 (n = 11) 1 (n = 13) ns
The depicted data have been published elsewhere by our group. For further information on the data and the methods, see Vaaler AE et al. BMC Psychiatry. 2009;
9: 63 [25]. *Fisher exact tests. # Of a total of 7 patients, 3 were on lamotrigine, 3 on carbamazepine, 1 was on valproate. &Cannabis. AUDS: Acute Unstable
Depressive Syndrome; MDE: Major Depressive Episode; ns: not significant.
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At clinical neurological examination, three AUDS
patients and one control patient had signs of CNS
pathology. One AUDS patient had ophtalmoplegia and
bilaterally inverted plantar reflexes (positive Babinski’s
sign), whereas another had inverted plantar reflexes as
the only sign of pathology. The third patient had bilateral
horizontal nystagmus. In the control group, there was a
unilaterally inverted plantar reflex in one patient [25].
The AUDS patients had significantly higher temporal
delta band amplitude than the MDE patients. Delta
asymmetry was larger in AUDS than MDE in all
regions. The delta activity dominated in the right hemi-
sphere. Twelve of 16 AUDS patients had temporal delta
amplitude above 8.9 μV as compared to 3 of 16 MDE
patients. Three MDE - and 11 AUDS patients had abso-
lute temporal delta amplitude side difference above
0.1 μV [26].
There were no statistical differences between AUDS
and MDE patients with respect to antiepileptic medica-
tion, benzodiazepine intake, drug abuse, alcohol con-
sumption and alcohol withdrawal symptoms.
Results from SOMAS are shown in Table 2. At admis-
sion and during the first 2 weeks AUDS patients had
significantly higher SOMAS scores for any given item
(average score at admission 6.6 ± 0.8), reflecting
increased symptom fluctuation and motor agitation, and
decreased insight and concern compared to MDE
patients (2.9 ± 0.7; p < 0.001). At three months follow-
up AUDS patients did no longer exhibit symptom fluc-
tuation. Yet they still scored high for motor restlessness
and lack of concern, although on a lower level.
MADRS, which measures the degree of mood depres-
sion, did not reveal any significant differences (Table 3).
Cognition, life events and life style changes (assessed as
MMST < 25, SRRS and LES, respectively) did not differ
between AUDS and MDE patients (data not shown).
Discussion
We have compared two groups of patients with depres-
sive disorders admitted to a psychiatric emergency unit.
AUDS patients presented with rapidly fluctuating mood
disturbances, motor agitation and relative lack of insight
and concern, whereas MDE patients showed rather
stable mood levels, motor retardation and better under-
standing of and greater interest in their symptoms. Dif-
ferences between AUDS and MDE patients were present
until remittance of the affective episodes. This may indi-
cate that AUDS and MDE are clinically distinct syn-
dromes. AUDS patients had significantly more often a
history of seizures and diagnose of epilepsy as well as
more abnormalities on standard and quantitative EEG.
Hence, atypical depressive disorders are not only fre-
quent in patients in tertiary epilepsy centers [35], but
seizures, epilepsy and EEG abnormalities are also over-
represented in AUDS patients in psychiatric emergency
units.
Our pre-study observations indicated that SOMAS
measures a different concept than depression. This was
supported by the present study. Whereas no differences
between groups were observed with MADRS (suggesting
that the level of mood decrease was the same), all
SOMAS items were significantly different between
AUDS and MDE patients at almost any given time
point. Symptom fluctuation (Item A) was the only item
that was no longer different between groups at 3
months follow-up. Motor agitation and lack of insight
(Item B-D) gradually diminished during the observation
period, but remained rather pronounced until the end.
Agitation, defined as unusual motor restlessness accom-
panied by emotional tension, is frequently encountered
in depressive disorders [36,37]. The present data indi-
cate that in AUDS patients, agitation is a core symptom.
The presence of agitation has clinical implications for
the choice between antidepressants and antiepileptic
mood stabilizers [36-39]. Antiepileptic mood stabilizers
have a positive effect on agitated depression with or
without organic brain disorders [36,40], but antidepres-
sants are sometimes detrimental in these conditions
[38,39]. Interestingly, whereas symptom fluctuation and
motor agitation decreased in AUDS patients with time,
Table 2 AUDS and MDE groups assessed by the Symptomatic Organic Mental Disorder Assessment Scale (SOMAS)
SOMAS 2 days after Admittance 4-6 days after admittance 14-16 days after admittance 3 months after admittance
AUDS MDE P value AUDS MDE P value AUDS MDE P value AUDS MDE P value
Item A 5.7 ± 1.5 2.3 ± 0.8 <0.001 4.6 ± 1.7 2.1 ± 0.7 <0.001 4.5 ± 2.0 1.8 ± 0.8 <0.001 2.3 ± 1.2 1.7 ± 0.6 ns
Item B 9.9 ± 0.5 6.3 ± 2.0 <0.001 9.6 ± 1.3 6.9 ± 1.7 <0.001 9.7 ± 1.3 7.2 ± 1.7 <0.001 9.7 ± 1.0 7.9 ± 2.0 0.007
Item C 5.8 ± 2.3 1.2 ± 0.5 <0.001 4.0 ± 2.2 1.1 ± 0.5 <0.001 4.4 ± 2.3 1.1 ± 0.3 <0.001 3.1 ± 1.5 1.2 ± 0.6 <0.001
Item D 7.8 ± 1.8 2.1 ± 1.1 <0.001 7.7 ± 1.5 2.0 ± 0.9 <0.001 7.6 ± 1.7 1.9 ± 0.9 <0.001 6.9 ± 1.8 2.3 ± 1.7 <0.001
Item E 3.6 ± 1.6 2.6 ± 1.2 0.04 4.0 ± 1.6 2.2 ± 1.1 0.002 3.9 ± 1.4 2.6 ± 1.1 0.008 4.7 ± 1.4 2.2 ± 0.8 <0.001
Average item A-E 6.6 ± 0.8 2.9 ± 0.7 <0.001 6.0 ± 1.0 2.9 ± 0.6 <0.001 6.0 ± 1.1 2.9 ± 0.6 <0.001 5.4 ± 0.8 3.1 ± 0.7 <0.001
AUDS and MDE groups were assessed using SOMAS at four different time points. For each item (A-E) a score from 0 to 10 was given. All values are shown as
mean ± sd. For details consider Methods and Appendix. AUDS: Acute Unstable Depressive Syndrome; MDE: Major Depressive Episode; ns: not significant.
Vaaler et al. BMC Neurology 2010, 10:67
http://www.biomedcentral.com/1471-2377/10/67
Page 4 of 7
lack of understanding (Item D) increased during the
observation period. At 3 months follow-up AUDS
patients often stated that they had given up searching
for an explanation and did not want to put further con-
cerns into it. This is perhaps in analogy to patients with
epilepsy who more often than others believe that their
life is controlled by external factors (fate, luck, chance)
rather than internal factors (efforts, skills) [41,42]. It can
be concluded that atypical depressive symptoms cannot
be classified by DSM-IV and that SOMAS provides dif-
ferent information than MADRAS. The advantage of
SOMAS is that it can be used to evaluate and classify
clinical symptoms suggestive of AUDS.
The interictal dysphoric disorder has a characteristic
chronic intermittent and pleomorphic symptomatology
[23]. Also the AUDS clinical syndrome features pleo-
morphic psychiatric symptoms, but it differs from inter-
ictal dysphoric disorder in that it has a more acute
onset and a more varied symptomatology including
behaviorioral problems such as aggression. Therefore,
patients with AUDS require acute psychiatric care.
However, episodic interictal psychiatric conditions
resembling interictal dysphoric disorder with slightly dif-
ferent characteristics are described and termed by differ-
ent authors in the same manner as the AUDS [3,23,43].
Core characteristics of the AUDS clinical picture has
similarities to some of the symptoms in these condi-
tions, for instance, according to Himmelhoch such
patients have “brief depressive dips with impulsive sui-
cide attempts” [43].
Clinical observations made by neurologists, psychia-
trists and epileptologists of epilepsy-specific psychiatric
syndromes have led to an expert consensus proposing a
new system of classification of these disorders [21].
These proposals are based on data primarily generated
in tertiary epilepsy centers. The present study suggests
that possibly, epilepsy-specific psychiatric syndromes
might also be identified in psychiatric emergency units.
Obviously, much larger patient populations must be stu-
died before such a claim can be verified. However, our
data indicate that assessment of AUDS patients is a pos-
sible approach to this issue in the future.
This study has a number of limitations and thus, the
present results must be interpreted with caution.
Patients were recruited in daily routine clinical practice
and the ward staff was not blinded to the outcome of
our assessment. We included patients with substance
abuse, alcohol withdrawal symptoms, antiepileptic drug
treatment and benzodiazepine intake. These factors
probably affected the expression of symptoms as well as
EEG recordings. However, in order to obtain a more
naturalistic study, we chose not to exclude these
patients [44]. The small number of subjects led to rela-
tively weak statistical power. However, nearly all
SOMAS-scores reached statistical significance, which
indicates a strong correlation between epileptic activity,
depression and the different SOMAS items. Further,
one might argue that our study was affected by a pre-
selection bias. Yet as stated earlier, previous studies on
the prevalence of depressive symptoms in epilepsy
populations have been affected by a similar selection
bias.
The study also has some significant advantages. It was
a prospective study in a naturalistic patient population
from a defined catchments area. All patients admitted
within a three-year period were evaluated for inclusion.
We have used a robust validated instrument with docu-
mented sensitivity to symptom fluctuation [27]. All
patients had EEG recordings shortly after admittance.
We have extensively screened for alcohol and illicit drug
use and medication serum levels. Moreover, we screened
for a broad range of confounding factors. Cognition, life
events and life style changes were assessed, but there
were no differences between the groups.
Conclusions
AUDS patients present with rapidly fluctuating mood
symptoms, motor agitation when depressed and relative
lack of insight and concern. These patients have more
often a history of seizures, diagnose of epilepsy and EEG
abnormalities than MDE patients. Whereas atypical
depressive disorders are frequently encountered in
patients in tertiary epilepsy centers [35], it seems that
seizures, epilepsy and EEG abnormalities are also over-
represented in AUDS patients in psychiatric emergency
units. Obviously, further studies are needed to corrobo-
rate these results. In a sentinel paper on epilepsy and
depression, Kanner complains that “neurologists and
psychiatrists [have] stopped talking to each other” [45].
It is time that both specialties join forces again. We sug-
gest that the study of AUDS patients may offer a new
approach to better understanding epilepsy and its asso-
ciation with depressive disorders.
Table 3 AUDS and MDE groups assessed by the
Montgomery and Åsberg Depression Rating Scale
(MADRS)
Time point after admittance AUDS MDE P value
Day 2 29.2 ± 8.9 34.6 ± 7.1 ns
Day 4-6 19.5 ± 8.9 22.7 ± 4.6 ns
Day 14-16 17.2 ± 10.5 19.0 ± 8.6 ns
3 months 9.5 ± 7.0 10.6 ± 6.9 ns
AUDS and MDE groups were assessed using MADRS at four different time
points. MADRS has a scoring scale that ranges from 0 (least depressed) to 60
(most depressed). A depressive episode is defined as MADRS ≥ 20. All values
are shown as mean ± sd. For details consider Methods. AUDS: Acute Unstable
Depressive Syndrome; MDE: Major Depressive Episode; ns: not significant.
Vaaler et al. BMC Neurology 2010, 10:67
http://www.biomedcentral.com/1471-2377/10/67
Page 5 of 7
Appendix
Symptomatic Organic Mental Disorder Assessment Scale
(SOMAS)
The ratings of all items are based on the investigator’s
personal examination of the patient, and/or information
in the case records and/or information from the hospital
ward staff.
The scorings are 1 - 10 on the following 5 items:
A: Degree of observable change in symptoms during the
previous 24 hours
1: The symptoms have been completely stable through-
out 24 hours.
3: Minor changes in symptoms during the past 24
hours (e.g., increased symptoms in the morning as in a
depressive episode).
5: Some change of symptoms (e.g., breakthrough of
depressive symptoms in hypomania).
8: Frequent alternation of symptoms, dominating more
than half of the day.
10: Rapid fluctuation of symptoms from one half hour
to the next.
B: Degree of motor retardation, rated during the period or
periods of the previous 24 hours in which the patient was
most depressed (modified from PANSS [28])
1: The patient has been almost completely immobile and
virtually unresponsive to external stimuli.
3: Movements are extremely slow, resulting in a mini-
mum of activity and speech. The patient is mostly sit-
ting idly or lying down.
5: The patient has slow movements, and speech may
be characterized by poor productivity, including long
response latency, extended pauses, or slow pace.
8: Slight diminution in rate of movements and speech.
10: No motor retardation.
C: Degree of increased motor activity, rated during the
period or periods the previous 24 hours when the patient
was most depressed (modified from PANSS [28])
1: No increased motor activity.
3: The patient is slightly agitated with hypervigilance
or has a tendency towards mild overarousal. The speech
is slightly pressured.
5: The patient is clearly agitated and overaroused with
affected speech and motor activity.
8: Marked excitement dominates the period and restricts
attention and vital functions such as eating and sleeping.
10: The excitement is so extreme that interpersonal
interaction is virtually impossible. The patient has accel-
eration of speech and motor activity resulting in inco-
herence and exhaustion.
D: Degree of patient’s insight into his or her condition/
symptoms
1: Mature and thoroughly considered attempt at
explaining the condition. This explanation may or may
not be psychotic.
3: The patient has been thinking of various possible
explanations and has come up with a well-founded opi-
nion about some of them.
5: The patient wonders about different causes of the
condition, but is unsure.
8: The patient has one or several ideas about the
cause, without any considered argumentation.
10: Patient is totally bewildered to what has happened
or to what causes the condition.
X: Not possible to score; e.g. due to incapability to
communicate verbally.
E: Degree of the patient’s concern in finding an explanation
for his or her condition/symptoms
1: Considerable engagement in finding an explanation of
the condition.
3: Moderate engagement in finding an explanation of
the condition.
5: Some engagement in finding an explanation of the
condition.
8: Minimal engagement in finding an explanation of
the condition.
10: The patient does not wonder at all what may have
caused the condition.
X: Not possible to score; e.g. due to incapability to
communicate verbally.
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